Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens

Foteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Charikleia Gakiopoulou, Erasmia Psimenou, Tina Bagratuni, Alexandra Papathoma, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos, Efstathios Kastritis

Blood (2023) 142 (Supplement 1): 6756.

https://doi.org/10.1182/blood-2023-189926

Published: 2023

Journal Articles

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

Eftathios Kastritis, Maria Gavriatopoulou, MD, Maria Roussou, MD, Magdalini Migkou, MD, Despina Fotiou, BMBS, MA, Ioanna Dialoupi, MD, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Foteini Theodorakakou, MD, Asimina Papanikolaou, MD, Erasmia Psimenou, MD, Kimon Stamatelopoulos, MD, Efstathios Manios, MD, Maria Irini Tselegkidi, MD, Argyrios Ntalianis, MD, Stavroula Giannouli, MD PhD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1894.

https://doi.org/10.1182/blood-2019-128208

Published: 2019

Journal Articles

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Eftathios Kastritis, Nikolaos Kanellias, MD, Foteini Theodorakakou, MD, Erasmia Psimenou, MD, Charikleia Gakiopoulou, MD, Smaragdi Marinaki, Maria Roussou, MD, Maria Gavriatopoulou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1776.

https://doi.org/10.1182/blood-2019-126385

Published: 2019

Journal Articles

Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment

Meletios A. Dimopoulos, MD, Maria Roussou, MD, Eftathios Kastritis, Alexandra Margeli, PhD, Evangelos Eleutherakis-Papaiakovou, MD, Ioannis Ntanasis-Stathopoulos, MD, Nikolaos Kanellias, MD, Gerasimos-Petros Papassotiriou, PhD, Despina Fotiou, MD, Magdalini Migkou, MD, Maria Gavriatopoulou, MD, Erasmia Psimenou, MD, Ioannis Papassotiriou, PhD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 1877.

https://doi.org/10.1182/blood-2019-123912

Published: 2019

Journal Articles

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS)

Eftathios Kastritis, Ioannis Papassotiriou, PhD, Maria Roussou, MD, Maria Gavriatopoulou, MD, Mantzou Aimilia, PhD, Erasmia Psimenou, MD, Smaragdi Marinaki, Charikleia Gakiopoulou, MD, Alexandra Margeli, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, BMBS, MA, Ioannis Ntanasis-Stathopoulos, MD, Gerasimos-Petros Papassotiriou, PhD, Aristea-Maria Papanota, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3126.

https://doi.org/10.1182/blood-2019-125305

Published: 2019

Journal Articles

Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd

Blood (2018) 132 (Supplement 1): 3246.

https://doi.org/10.1182/blood-2018-99-112764

Published: 2018

Journal Articles

Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD)

Blood (2018) 132 (Supplement 1): 3248.

https://doi.org/10.1182/blood-2018-99-111608

Published: 2018

Journal Articles

Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients

Blood (2018) 132 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2018-99-112851

Published: 2018

Journal Articles

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis

Efstathios Kastritis, Ioannis Papassotiriou, Giampaolo Merlini, Paolo Milani, Evangelos Terpos, Marco Basset, Athanasios Akalestos, Francesca Russo, Erasmia Psimenou, Filia Apostolakou, Maria Roussou, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Dimitrios C. Ziogas, Elektra Papadopoulou, Constantinos Pamboucas, Meletios A. Dimopoulos, Giovanni Palladini

Blood (2018) 131 (14): 1568–1575.

https://doi.org/10.1182/blood-2017-12-819904

Published: 2018

Includes: Supplemental data

Journal Articles

Efficacy of Lenalidomide As Salvage Therapy for Patients with AL Amyloidosis

Blood (2017) 130 (Supplement 1): 3118.

https://doi.org/10.1182/blood.V130.Suppl_1.3118.3118

Published: 2017

Journal Articles

Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis

Efstathios Kastritis, MD, Giampaolo Merlini, MD, Ioannis Papassotiriou, PhD, Paolo Milani, MD, Evangelos Terpos, Marco Basset, MD, Athanasios Akalestos, Francesca Russo, Erasmia Psimenou, Filia Apostoloakou, Maria Roussou, Maria Gavriatopoulou, Despina Fotiou, Dimitrios Ziogas, Constantinos Pamboucas, Elektra Papadopoulou, Meletios A Dimopoulos, Giovanni Palladini, MD PhD

Blood (2016) 128 (22): 648.

https://doi.org/10.1182/blood.V128.22.648.648

Published: 2016

Journal Articles

Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib

Efstathios Kastritis, MD, Maria Gavriatopoulou, Maria Roussou, Despina Fotiou, Dimitrios Ziogas, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Ioannis Panagiotidis, Erasmia Psimenou, Elektra Papadopoulou, Constantinos Pamboucas, Efstathios Manios, MD, Harikleia Gakiopoulou, MD, Anna Tasidou, MD, Stavroula Giannouli, Evangelos Terpos, MD PhD, Meletios A Dimopoulos

Blood (2016) 128 (22): 4500.

https://doi.org/10.1182/blood.V128.22.4500.4500

Published: 2016

Journal Articles

Cardiac and Renal Complications of Carfilzomib Therapy in Patients with Multiple Myeloma

Meletios A. Dimopoulos, Maria Roussou, Maria Gavriatopoulou, Erasmia Psimenou, Dimitrios Ziogas, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Ioannis Panagiotidis, Argyrios Ntalianis, Evangelos Repasos, Elektra Papadopoulou, Kimon Stamatelopoulos, Efstathios Manios, Constantinos Pamboukas, Sofoklis Kontogiannis, Evangelos Terpos, Efstathios Kastritis, MD

Blood (2016) 128 (22): 4491.

https://doi.org/10.1182/blood.V128.22.4491.4491

Published: 2016

Journal Articles

Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival

Meletios A. Dimopoulos, Maria Roussou, Maria Gavriatopoulou, Despina Fotiou, Dimitrios Ziogas, Magdalini Migkou, Ioannis Panagiotidis, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Erasmia Psimenou, John N Boletis, Dimitra Bacharaki, Despoina Mparmparoussi, Charis Matsouka, Stavroula Giannouli, Evangelos Terpos, Efstathios Kastritis, MD

Blood (2016) 128 (22): 4492.

https://doi.org/10.1182/blood.V128.22.4492.4492

Published: 2016

Journal Articles

Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis

Efstathios Kastritis, Ioannis Papassotiriou, Evangelos Terpos, Maria Roussou, Maria Gavriatopoulou, Anna Komitopoulou, Chrysanthi Skevaki, Evangelos Eleutherakis-Papaiakovou, Constantinos Pamboucas, Erasmia Psimenou, Efstathios Manios, Stavroula Giannouli, Marianna Politou, Harikleia Gakiopoulou, Elektra Papadopoulou, Kimon Stamatelopoulos, Anna Tasidou, Meletios A. Dimopoulos

Blood (2016) 128 (3): 405–409.

https://doi.org/10.1182/blood-2016-02-702696

Published: 2016

Includes: Supplemental data

Journal Articles

Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis

Meletios A. Dimopoulos, Efstathios Kastritis, MD, Maria Roussou, Erasmia Psimenou, Maria Gavriatopoulou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Dimitrios Ziogas, Ioannis Panagiotidis, Despoina Fotiou, Eftychia Kafantari, Stavroula Giannouli, Sofoklis Kontogiannis, Evangelos Terpos

Blood (2015) 126 (23): 1832.

https://doi.org/10.1182/blood.V126.23.1832.1832

Published: 2015

Journal Articles

Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents

Efstathios Kastritis, MD, Maria Roussou, Evangelos Terpos, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Sofoklis Kontogiannis, Theofanis Apostolou, Ioannis Boletis, Constantinos Pamboukas, Savvas Th. Toumanidis, Elektra Papadopoulou, Erasmia Psimenou, Meletios A. Dimopoulos, MD

Blood (2014) 124 (21): 2130.

https://doi.org/10.1182/blood.V124.21.2130.2130

Published: 2014

Journal Articles

Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes

Efstathios Kastritis, MD, Ioannis Papassotiriou, PhD, Evangelos Terpos, Athanassios Akalestos, Erasmia Psimenou, Filia Apostolakou, Maria Roussou, Maria Gavriatopoulou, Elisavet Kaldara, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Constantinos Pamboucas, Evangelos Kostis, Sofoklis Kontogiannis, Savvas Th. Toumanidis, Ioannis Boletis, Meletios A. Dimopoulos

Blood (2014) 124 (21): 306.

https://doi.org/10.1182/blood.V124.21.306.306

Published: 2014

Journal Articles

Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

Meletios A. Dimopoulos, Maria Roussou, Evangelos Terpos, Erasmia Psimenou, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Marios Bakogeorgos, Despoina Mparmparoussi, Theodoros P. Vassilakopoulos, Dimitra Gika, Charis Matsouka, Ioannis Boletis, Kostas Konstantopoulos, Efstathios Kastritis, MD

Blood (2014) 124 (21): 4769.

https://doi.org/10.1182/blood.V124.21.4769.4769

Published: 2014

Journal Articles

Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction

Meletios A. Dimopoulos, MD, Evangelos Terpos, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Nikolaos Kanellias, Dimitrios Christoulas, Despoina Kalapanida, Despoina Mparmparoussi, Charis Matsouka, Sofoklis Kontogiannis, Evangelos Kostis, Erasmia Psimenou, Efstathios Kastritis

Blood (2013) 122 (21): 3176.

https://doi.org/10.1182/blood.V122.21.3176.3176

Published: 2013

NARROW

Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS)

Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd

Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD)

Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis

Efficacy of Lenalidomide As Salvage Therapy for Patients with AL Amyloidosis

Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis

Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib

Cardiac and Renal Complications of Carfilzomib Therapy in Patients with Multiple Myeloma

Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival

Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis

Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis

Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents

Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes

Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only